Drug Trial Radar · NCT05507515
A Phase 1 Study of ONO-2020 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Jul 29, 2022
Primary completion
Dec 24, 2023
Study completion Dec 24, 2023
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.
Conditions
- Healthy Volunteers
Interventions
ONO-2020Drug
ONO-2020 tablets
PlaceboDrug
Placebo tablets matching ONO-2020 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity, and type of treatment emergent adverse events (TEAEs)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Vital signs (blood pressure)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Vital signs (pulse rate)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Vital signs (body temperature)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Vital signs (respiratory rate)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- 12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Clinically significant abnormal telemetry electrocardiograms (ECGs)Time frame: Part A and D: Day 1
- Clinically significant abnormal physical examination findingsTime frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Ophthalmologic examination findings (pupil size and pupillary light reflex)Time frame: Part A, C and D: From Day 1 up to Day 7, Part B and E: From Day 1 up to Day 21
- Clinically abnormal findings in Mini-International Neuropsychiatric Interview Screen (M.I.N.I.-Screen)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
- Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.